The Different Faces of Angiogenesis in Neuroblastoma by Pietro Luigi Poliani & Domenico Ribatti
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






The Different Faces  
of Angiogenesis in Neuroblastoma 
Pietro Luigi Poliani1 and Domenico Ribatti2 
1Department of Pathology, University of Brescia, Brescia  
2Department of Human Anatomy, University of Bari, Bari 
Italy 
1. Introduction 
Neuroblastoma represents one of the most frequent solid tumour of childhood, arising along 
the sympathetic nervous system, most frequently in the adrenal gland. Clinically, 
neuroblastoma is an heterogeneous entity and prognosis vary widely according to different 
biological variables (such as DNA ploidy and MYCN amplification), patient age, anatomical 
location and tumour stage at diagnosis (Maris et al., 2002; Schwab et al., 2003). 
Unfortunately, the majority of patients show systemic disease at the time of diagnosis, with 
rapid tumour progression and fatal outcome. According to this clinical heterogeneity, the 
International Pathology Classification System has identified a broad spectrum of different 
histological features, ranging from undifferentiated/poorly differentiated to 
differentiating/fully differentiated lesions, with progressive increase in the Schwannian 
component and differentiation of neuroblastic cells towards a mature ganglionic phenotype 
(Shimada et al., 1999; Cohn et al., 2009). Of note, as others paediatric tumours, 
neuroblastoma displays the capacity to undergo spontaneous regression and/or 
differentiation into benign fully mature lesions, with increase of Schwannian stroma and 
differentiating/differentiated neuroblasts, that biologically resemble ganglion cells, directly 
correlated with tumour maturation and better prognosis (Ambros et al., 2002; Haas et al., 
1988). Indeed, differentiating and well-differentiated neuroblastic lesions with low 
mitosis/karyorrhexis index are classified by International Neuroblastoma Pathology 
Classification consensus as tumours associated with a better prognosis and a higher rate of 
cure (Peuchmaur et al., 2003; Shimada et al., 1999). 
The role of angiogenesis in tumour growth and progression represents a major subject in 
modern oncology. It is generally accepted that angiogenesis promotes tumour growth and is 
essential for invasion of surrounding tissues and metastasis. Angiogenesis is tidily regulated 
by the balance of numerous pro-angiogenic and anti-angiogenic factors. Tumours that fail to 
recruit new blood vessels remain dormant while tumours characterized by prominent neo-
angiogenesis growth faster and display an aggressive behaviour (Carmeliet et al., 2003; 
Ribatti et al., 1999). A large variety of pro-angiogenic factors have been identified so far to 
play an important role in the induction of angiogenesis in neuroblastic lesions, including 
vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), fibroblast growth factor-2 
(FGF-2), and angiopoietins (Eggert et al., 2000; Ribatti et al., 1998). High vascular index in 
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neuroblastoma have been demonstrated to correlate with poor prognosis, suggesting a tide 
correlation between aggressive tumour behaviour and active angiogenesis (Katzenstein et 
al., 2000). These observations point out to an important role of promising emerging anti-
angiogenic strategies for the treatment of neuroblastoma, a lesion characterized by a high 
degree of vascularity (Pastorino et al., 2009; Marimpietri et al., 2007; Ribatti et al., 2005; 
Rossler et al., 2008). In this review the recent findings in neuroblastoma angiogenesis as well 
as the most recent advances in the development of novel anti-angiogenetic approaches in 
the treatment of neuroblastoma will be discussed. 
However, although it has been well established that angiogenesis in neuroblastoma 
correlates with tumour progression, advanced stages and worst prognosis (Carmeliet et al., 
2003), little is known about the role of angiogenesis in the maturation phase of 
undifferentiated neuroblastomas towards a more differentiated phenotype. As previously 
described, neuroblastic lesions show a wide spectrum of histological variability that reflects 
different steps of tumour maturation, whose molecular mechanisms are not still fully 
understood. Recent findings have suggested that the same molecular pathways driving the 
development of normal neuroectodermal-derived tissues might also be involved in 
neuroblastoma maturation (Christiansen et al., 2000; Hoehner et al., 1998). Between these, 
angiogenesis plays a key role during neural differentiation, exerting a trophic activity 
(Ribatti et al., 2007; Kitlinska et al., 2005). In line with these observations, recent findings 
have shown that specific angiogenetic pathways play a crucial role during the maturation 
phase of neuroblastic tumours and contribute to neuroblast maturation (Poliani et al., 2007). 
Finally, it has been suggested that cross-talk between Schwann cells and neuroblasts 
influences the biology and clinical behaviour of neuroblastic tumours (Kwiatkowski et al., 
1998). Schwannian stroma rich tumours have been shown to have low vascularity, 
suggesting that Schwann cells may influence neuroblast biology by producing soluble 
factors capable of inducing neuroblast differentiation and inhibiting tumour neo-
angiogenesis (Ambros et al., 1996). 
These observations indicate a different role of different angiogenetic pathways in 
neuroblastoma, with some of them mimicking physiological steps leading to maturation of 
vasculature in developing normal neuroectodermal-derived tissues, thus contributing to the 
maturation stage of neuroblastic tumours, and others that sustain tumour neo-angiogenesis 
and contribute to tumour aggressiveness and progression. 
In conclusions, this review will focus on the most recent advances in the field of 
angiogenesis in neuroblastic lesions keeping in mind that understanding the mechanisms of 
angiogenesis will provide the basis for a rational and targeted approach to the development 
of specific treatments targeting tumour angiogenesis or promoting neuroblastic maturation 
in patients affected by neuroblastoma. 
2. Role of angiogenesis in tumour growth and progression 
During solid tumour development, an avascular phase precede the fully active vascular 
phase. Assuming that tumour development is dependent on angiogenesis and that this 
depends on the release of angiogenic factors, the acquisition of an angiogenic ability can be 
considered as an expression of progression from neoplastic transformation to tumour 
growth and metastasis (Ribatti et al., 1999). The avascular phase appears to correspond to a 
small colony of neoplastic cells that reaches a steady state before proliferation and 
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acquisition of an invasive behaviour. In fact, dormant tumours can been found during 
autopsies of individuals who died of causes other than cancer (Black & Welch, 1993). 
Moreover, in situ carcinomas are a frequent finding in individuals aged 50 to 70 years who 
died of trauma, but are diagnosed in only 0.1% of patients during life. Malignant tumours 
can grow beyond the critical size of 2 mm at their site of origin by exploiting the host’s pre-
existing vessels. These finding support the notion that only a very small subset of dormant 
tumours enters the vascular phase and rapidly progress. 
The role of angiogenesis in tumour growth has become evident thanks to a series of studies 
demonstrating that tumour progression is clearly related to the degree of angiogenesis, as 
seen in different types of tumours, including neuroblastoma. In fact, high vascular density 
and active angiogenesis in neuroblastoma have been shown to correlate with poor prognosis 
and tumour progression (Ribatti et al., 2004). 
Tumour angiogenesis is strictly linked to the switch in the balance between positive and 
negative regulators, and mainly depends on the release by neoplastic cells of specific growth 
factors for endothelial cells, that stimulate the growth of the host’s blood vessels or the 
down-regulation of natural angiogenic inhibitors. In normal tissues, vascular quiescence is 
maintained by the dominant influence of endogenous angiogenic inhibitors over angiogenic 
stimuli. This switch depends on increased production of one or more positive regulators of 
angiogenesis, such as vascular endothelial growth factor (VEGF), fibroblast growth factor-2 
(FGF-2), IL-8, placental growth factor (PlGF), transforming growth factor- (TGF-), platelet 
derived growth factor (PDGF), pleiotrophins and others. These factors can be directly 
produced by tumour cells, mobilized from the extracellular matrix, or released from host 
cells recruited to the tumour. The switch clearly involves more than a simple up-regulation 
of angiogenic activity and has thus been regarded as the result of the net balance between 
positive and negative regulators (Ribatti et al., 2007). 
Considerable differences exist between normal and tumour vasculature. Tumour 
endothelial cells may divide up to 50 times more frequently than normal endothelial cells 
and are qualified by peculiar molecular and morphological features, mostly related to an 
immature phenotype. This immaturity of tumour vessels led H. Dvorak to define a tumour 
as “a wound that never heals” (Dvorak, 1986). 
Moreover, although the tumour vasculature originates from the host vessels engaging 
similar angiogenetic mechanisms, the organization may differ dramatically depending on 
the tumour type and location and tumour-associated blood vessels display many structural 
and functional abnormalities (Ribatti et al., 2006). Their unusual leakage, rapid growth and 
remodelling capacity, along with the expression of distinctive surface molecules, mediate 
the dissemination of neoplastic cells into the bloodstream and contribute to maintain the 
tumour microenvironment. Similar to normal blood vessels, tumour vasculature consists of 
endothelial cells, pericytes and their enveloping basement membrane. Common features, 
regardless of their origin, size and growth pattern, include the absence of an hierarchy, the 
formation of large-caliber sinusoidal vessels and a markedly heterogeneous density. 
A complex interrelationship has also been described between tumour hypoxia and tumour 
angiogenesis. Hypoxia in tumours develops both as chronic hypoxia, resulting from long 
diffusion distances between tumour vessels, and/or acute hypoxia, resulting from a 
transient collapse of tumour vessels. Most of the solid tumours contain a hypoxic 
microenvironment, a condition that is associated with poor prognosis and resistance to 
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treatment. Of note, the production of important angiogenic factors, such as FGF-2, VEGF, 
TGF- , TNF- and IL-8, is regulated by hypoxia. Accordingly, VEGF-mRNA expression is 
rapidly and reversibly induced by exposure of cultured endothelial cells to low PO2 (Levy et 
al., 1995). 
There are also increasing evidences that stromal cells as well as inflammatory cells within 
the tumour, such as lymphocytes, neutrophils, macrophages and mast cells, cooperate with 
endothelial and cancer cells in promoting angiogenesis, by mean of the production of 
different growth factors and proteases (Parket et al., 2000). 
Finally, it is increasingly recognized that oncogenes, such as mutated RAS or SRC, may also 
contribute to tumour angiogenesis by enhancing the production of pro-angiogenic factors, 
such as VEGF and inhibitors of angiogenesis such as thrombospondin-1 (TSP-1) (Rak et al., 
1995; Ellis et al., 1998). In line with these observations it has been demonstrated that down-
regulation of RAS-oncogene in a melanoma driven by doxycycline-inducible ras led to 
tumour regression within 12 days (Tang et al., 2005) and that cells expressing low levels of 
RAS remain dormant and non-angiogenic, whereas cells expressing high levels of RAS 
produce a full-blown tumours with marked up-regulation of TSP-1 levels (Watnick et al., 
2003). 
3. Role of angiogenesis in the maturation phase of neuroblastic lesions 
As described previously a correlation between angiogenesis and poor outcome in human 
neuroblastomas have been demonstrated (Eggert et al., 2000; Ribatti et al., 2001; Ribatti et al., 
2002; Ribatti et al., 2004). However, little is known about the role of angiogenesis in the 
maturation of undifferentiated neuroblasts towards a mature ganglionic phenotype. In fact, 
as others paediatric tumours, neuroblastoma displays the capacity to undergo spontaneous 
regression in infants and/or differentiation into benign ganglioneuroma in older patients 
(Pritchard et al., 1994; Maris et al., 2002). This peculiarity reflects the wide spectrum of 
histological variability within the neuroblastic tumours, ranging from undifferentiated to 
differentiating or fully differentiated lesions (Figure 1, Panel A). Moreover, along with 
young age (<18 months) and localized disease, differentiation has been strongly correlated 
to a better prognosis (Ambros et al., 1996). Spontaneous or treatment-induced maturation 
characterizes a subgroup of neuroblastomas and constitutes the basis for maturation 
targeting therapies, such as retinoic acid treatment (Ferrari-Toninelli et al., 2010; Matthay et 
al., 1999; Mora et al., 2004; Giannini et al., 2000). Nevertheless, the molecular mechanisms 
that drive maturation of neuroblastic lesions are still poorly understood. Schwannian stroma 
cells have been claimed to be implicated in differentiation of neuroblastomas (Coco et al., 
2005; Ambros et al., 1996) as well as a large variety of transcriptional factors and different 
genes involved in neural development and differentiation of normal neuroectodermal-
derived tissues (Hoehner et al. 1998; Kitlinska et al., 2005; Ferrari-Toninelli et al., 2010; 
Christiansen et al., 2000; Koppen et al., 2008). Gene expression profiles studies recently 
allowed to identify genes differentially expressed between undifferentiated and 
differentiated neuroblastic lesions. These studies led to the identification of different 
molecular patterns of differentiation, ranging from undifferentiated pre-
adrenergic/adrenergic neuroblastomas with frequent MYCN amplification to cholinergic-
committed or fully cholinergic neuroblastomas that may reflect a fully differentiated 
phenotype (Bourdeaut et al., 2009). 
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Angiogenesis has been described to plays a key role during neural differentiation, exerting a 
trophic activity and promoting the maturation of vasculature in developing normal 
neuronal tissue (Kitlinska et al., 2005). We have recently described that the human 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a transmembrane 
glycoprotein that belongs to the carcinoembryonic antigen (CEA) gene family, is peculiarly 
expressed in the microvessels among differentiating neuroblastic/ganglion cells and is 
related to the tumour maturation (Poliani et al., 2007). CEACAM1 exerts a large variety of 
biological functions, including a strong pro-angiogenic role during the activation phase of 
angiogenesis, being expressed in the developing immature blood vessels of both in newly 
normal formed vessels and in different tumours (Wagener et al., 2000; Volpert et al., 2002). 
Microvascular endothelial cells over-expressing CEACAM1 show up-regulation of various 
angiogenic factors, including VEGF, angiopoietins and IL-8, indicating that CEACAM1 
expression in endothelial cells switches them to an angiogenic phenotype, a mechanism 
active during the formation of new vessels in physiological conditions such as wound 
healing and embryonic development, but silent in endothelial cells of large mature quiescent 
vessels (Wagener et al., 2000). Accordingly, CEACAM1 has been found to be expressed 
transiently in the microvessels of the developing central nervous system (Sawa et al., 1994), 
suggesting a role in the induction of capillary formation during tissue development rather 
than in the maintenance of mature vasculature. Interestingly, CEACAM1 have been also 
found to be expressed in microvessels of the normal adrenal gland, particularly during fetal 
development (Figure 1, Panel B). We have investigated the role of CEACAM1/VEGF-
mediated angiogenesis in neuroblastic tumours at different stages of maturation, 
demonstrating that CEACAM1 is transiently expressed in microvessels among 
differentiating neuroblast/ganglion cells whereas it is completely absent in poorly 
differentiated/undifferentiated tumours as well as in fully mature ganglioneuromas. 
Interestingly, strong VEGF expression was observed in differentiating neuroblast/ganglion 
cells adjacent to CEACAM1 positive microvessels (Figure 1, Panel C). In contrast, 
CEACAM1 is not expressed in poorly differentiated/undifferentiated neuroblastomas, 
characterized by high levels of VEGF and VEGFR (FLK-1), in keeping with several studies 
reporting the association of VEGF expression with tumour aggressiveness and a poor 
prognosis (Backman et al., 2002; Eggert et al., 2000) and suggesting that in poorly 
differentiated/undifferentiated lesions VEGF expression is independent from CEACAM1 
and may follow different molecular pathways. Accordingly, we have also demonstrated that 
conditioned medium from human neuroblastoma SH-SY5Y cell lines collected at different 
stages of differentiation caused a progressive in vitro up-regulation of CEACAM1 
expression in human umbilical vein endothelial cells (Poliani et al., 2007). 
Overall, our data indicate a crucial role of CEACAM1/VEGF mediated angiogenesis during 
the maturation phase of neuroblastic tumours, mimicking physiologic events leading to 
maturation of vasculature in developing neuroectodermal-derived tissues. Endothelial up-
regulation of CEACAM-1 activate angiogenesis via increased expression of VEGF in 
neuroblastic cells triggering an angiogenic cascade that promote and maintain VEGF 
induced angiogenesis. This feature could be involved in the complex mechanism driving the 
switch from immature to differentiating forms of neuroblastomas. Conversely, in poorly 
differentiated/undifferentiated neuroblastomas the VEGF sustained angiogenesis does not 
reproduce physiological steps, it is associated with tumour aggressiveness and may involve 
other molecular pathways. 
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Fig. 1. Histological variants of neuroblastic tumours and CEACAM1/VEGF expression. 
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Panel A: neuroblastic lesions show a wide spectrum of different histological variants 
reflecting different maturation phases, ranging from undifferentiated/poorly differentiated 
neuroblastomas with neuronal rosettes (upper left images), differentiating lesions with 
larger cells acquiring a ganglionic phenotype (upper right images), mixed lesions 
(ganglioneuroblastomas) with both immature and fully mature ganglionic cells (lower left 
panels) and fully differentiated lesions with mature ganglion cells and progressive increase 
in the Schwannian component (lower right panels). Panel B: CEACAM1 is only weakly 
expressed in the microvessels of normal adult adrenal gland (left images) while strong and 
diffuse expression is present in the developing microvessels of normal fetal adrenal gland 
(right images). Panel C: Serial sections from a representative case of undifferentiated 
neuroblastoma showing no expression of CEACAM1 in the tumour vessels that stain 
positive for CD31 (upper left images). On the contrary, differentiating neuroblastomas show 
CEACAM1-positive microvessels adjacent to differentiating neuroblastic/ganglion cells 
(upper right images). Serial tissue sections from a representative case of differentiating 
neuroblastoma show CEACAM1-positive microvessels adjacent to VEGF-positive 
differentiating neuroblastic cells (lower images, on the right a detail at higher 
magnification). 
4. Role of Schwann cells in angiogenesis 
As previously described, neuroblastic lesions exhibits a large variety of histological 
features reflecting the different steps of tumour maturation, ranging from immature 
neuroblastoma, with small undifferentiated neuroblasts with scarce Schwannian stroma, 
to progressively maturing neuroblastomas composed of larger neuroblastic/ganglion-like 
cells with abundant Schwannian stroma. Diagnostic categories of Schwannian stroma-
rich/dominant tumours include mature and maturing ganglioneuroma and 
ganglioneuroblastoma of intermixed and nodular type. Categories of Schwannian stroma-
poor neuroblastoma tumours include differentiating, poorly differentiated and 
undifferentiated (Shimada et al., 1999). Importantly, the increasing presence of 
Schwannian stroma and differentiating/differentiated neuroblasts, that biologically 
resemble ganglion cells, directly correlates with tumour maturation and better prognosis, 
with the exception of nodular ganglioneuroblastoma, (Peuchmaur et al., 2003; Nagoshi et 
al., 1992). 
Interestingly, in addition to a more differentiated phenotype, Schwannian stroma rich 
tumours also display low vascularity (Meitar et al., 1996). A correlation between low 
vascular density and absence of microvascular proliferation in Schwannian stroma-rich 
tumours have been demonstrated (Peddinti et al., 2007). On the contrary, high vascular 
index and abnormal blood vessels have been associated to clinical aggressiveness in 
Schwannian stroma-poor neuroblastoma tumours (Meitar et al., 1996; Peddinti et al., 
2007). 
This association between abundant Schwannian stroma, neuronal differentiation and 
decrease vascularity had led to the hypothesis that Schwann cells may secrete soluble factors 
capable of inducing neuroblast differentiation and inhibit angiogenesis (Huang et al., 2000). 
In fact, Schwann cells have been shown to secrete potent angiogenesis inhibitors, such as 
secreted protein acid rich in cysteine (SPARC) and pigment epithelium-derived factor 
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(PEDF) (Chlenski et al., 2002; Crawford et al., 2001). Moreover, angiogenesis is inhibited in 
neuroblastoma xenograft model in which mouse Schwann cells were induced to infiltrate 
the tumour by engrafting neuroblastoma cells in the sciatic nerve of nude mice (Liu et al., 
2005). Moreover, significantly higher number of cancer-associated fibroblasts have been 
demonstrated in Schwannian stroma-poor tumours compared to Schwannian stroma 
rich/dominant ganglioneuroblastomas/ganglioneuromas, consistent with the established 
pro-angiogenic function of cancer-associated fibroblasts (Zeine et al., 2009). 
5. Novel treatments targeting angiogenesis 
It has been already discussed in the previous paragraphs that high vascularity is a peculiar 
feature of neuroblastoma and promote tumour growth and aggressiveness. A large 
spectrum of angiogenic factors, including VEGF, have been reported to be expressed in 
neuroblastomas. Understanding the key mechanisms promoting angiogenesis in 
neuroblastoma represent a clue step in the development of effective anti-angiogenic 
strategies. The following paragraphs will aid to summarize the state of the art of the most 
current and experimental anti-angiogenic strategies in the treatment of neuroblastoma. 
5.1 Retinoids 
Retinoic acid has been shown to induce neuroblastoma maturation throughout different 
molecular pathways (Ferrari-Toninelli, 2010). In patients after autologous stem cell 
transplantation retinoic acid has been introduced as a maintenance treatment (Matthay et 
al., 1999). The synthetic retinoid N-(4-hydroxyphenyl) retinamide (fenretinide, HPR) inhibits 
human neuroblastoma cell growth through the induction of programmed cell death 
(Ponzoni et al., 1995). The contribution of retinoic acid in the control of tumour angiogenesis 
has been recently demonstrated. HPR inhibits angiogenesis induced by neuroblastoma 
specimens implanted onto the chorioallantoic membrane (CAM) (Ribatti et al., 2001). 
Moreover, retinoic acid have been also shown to induce expression of the endogenous 
angiogenesis inhibitor TSP-1 (Castle et al., 1992).  
5.2 TNP-470 
TNP-470 treatment have been shown to induce a reduction of tumour growth and 
microvascular density in mouse model xenograft of poorly differentiated human 
neuroblastoma cell line SHSY5Y. Moreover, TNP 470 treatment improved animal survival 
and reduced tumour growth of primary and metastatic murine neuroblastoma (Nagabuchi 
et al., 1997). Interestingly, TNP-470 also effectively inhibits neuroblastoma growth in 
animals with minimal disease treated before tumour were clinically apparent after 
subcutaneous injection of neuroblastoma cells. Furthermore, when TNP-470 is administered 
to animals with small tumours, the rate of growth is reduced, while does not significantly 
altered the tumour growth rate when it is administered to animals with large tumours. 
Moreover, TNP-470-treated tumours exhibited striking chromaffin differentiation, 
suggesting that by inhibiting angiogenesis, TNP-470 induces metabolic stress resulting in 
chromaffin differentiation (Katzenstein et al., 1999). A further study, confirmed that TNP-
470 effectively inhibits neuroblastoma xenograft growth when administered as a single 
agent or in association with other chemotherapic agents (Shusterman et al., 2001), indicating 
that TNP-470 may be useful as adjuvant therapy for high-risk neuroblastoma. 
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Kaicker et al. (2003) investigated the anti-angiogenic and anti-tumour properties of 
thalidomide in a xenograft model of human neuroblastoma. Indeed, thalidomide treatment 
did not significantly alter tumour growth as compared with control mice injected with 
neuroblastoma cells. However, thalidomide suppressed angiogenesis, as demonstrated both 
by fluorescent angiography and immunohistochemical staining, and induces apoptosis of 
endothelial cells in neuroblastoma xenografts (Kaicker et al., 2003). 
5.4 Endostatin 
Davidoff et al. (2001) developed a gene therapy approach in which the genes encoding for 
endostatin were delivered to murine neuroblastoma cells prior to inoculation of tumour 
cells into syngenic immunocompetent mice. Although the effect of either angiogenesis 
inhibition or immunomodulation alone resulted in only a modest delay in tumour growth, 
when these approaches were used in combination, prevention of the formation of 
appreciable tumours was effected in 63% mice (Davidoff et al., 2001). Interestingly, 
continuous administration of recombinant endostatin resulted even in a more significant 
tumour regression as compared to intermittent administration in neuroblastoma xenografts 
(Kuroiwa et al., 2003). Streck et al. (2004) evaluated the influence of a pre-existing primary 
neuroblastoma xenografts on the growth of a new second subcutaneously injected tumour, 
hypothesizing that an existing primary tumour could inhibit the growth of a secondary 
tumour, in part mediated by tumour release of endostatin. Decreased angiogenesis and 
increased apoptosis were seen in the secondary tumours, along with decrease of the weight 
of liver metastases. Although no difference in microvessel density was seen between groups, 
apoptosis was seen to significantly increase when the primary tumour was retained (Streck 
et al., 2004). 
5.5 Angiostatin 
Pre-clinical use of angiostatin in neuroblastoma has been studied in a gene therapy 
approach using a recombinant adenovirus encoding the human angiostatin kringle 1-3 
directly fused to human serum albumin HSA (Adk3-HSA). However, in human 
neuroblastoma xenograft models, intravenous injection of this vector showed no delay in 
tumour growth when compared to tumours treated with the control viral vector (Joseph et 
al., 2003). 
5.6 Thrombospondin 
ABT-510, a peptide derivative of TSP-1, significantly suppressed the growth of 
neuroblastoma xenografts established from two different MYCN-amplified cell lines. In 
combination with the histone deacetylase inhibitor valproic acid, ABT-510 inhibited more 
effectively the growth of xenografts compared to single-agent treatment (Yang et al., 2007). 
5.7 Bortezomib 
Bortezomib is a selective and reversible inhibitor of proteasome that shows a potent 
antitumor activity and that has been shown to inhibit proliferation and colony formation of 
neuroblastoma cell lines in a time- and dose-dependent manner. Moreover, bortezomib has 
been also shown to inhibit angiogenesis in CAMs stimulated by conditioned medium from 
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either neuroblastoma cell lines, xenografts and primary biopsy specimens. (Brignole et al., 
2006)  
5.8 Combined therapies 
Combined vinblastine and rapamycin therapy displayed synergistic inhibition of human 
neuroblastoma-related angiogenesis (Marimpietri et al., 2007). A significant inhibition of 
tumour growth and microvessel density was obtained in neuroblastoma-bearing mice when 
treated with vinblastine or rapamycin throughout the down-modulation of both VEGF and 
VEGFR-2 expression, as shown also by human neuroblastoma biopsy specimens in the 
CAM assay. (Brignole et al., 2006). The antitumor activity of bortezomib in combination with 
fenretinide has also been considered. The single compounds were able to induce a dose-
dependent inhibition of cell proliferation, but significant enhanced of the anti-proliferative 
effects has been demonstrated for the drugs used in combination. Bortezomib and 
fenretinide in association triggered increased apoptosis and significantly increase survival. 
Histologic examination and CAM assay of the primary tumours showed that combined 
therapeutic activity was strictly associated to anti-angiogenic mechanisms (Pagnan et al., 
2009). 
5.9 Anti-VEGF and anti-VEGF receptor-2 antibodies 
In a murine model of human neuroblastoma the monoclonal antibody against VEGF 
partially suppresses tumour growth (Kim et al., 2001). In a further study, topotecan, either in 
association with anti-VEGF treatment or alone, have been shown to significantly suppress 
neuroblastoma xenograft growth in comparison with controls or anti-VEGF treated mice 
(Kim et al., 2002b). Combined topotecan and anti-VEGF treatment significantly inhibited 
rebound tumour growth. Moreover, high-affinity blockade of VEGF, using the VEGF-TRAP, 
a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of 
IgG1, dramatically decreases tumour vasculature in a xenograft model of neuroblastoma 
(Kim et al., 2002b). Pre-clinical studies using bevacizumab, an inhibitor of VEGF, in 
neuroblastoma demonstrated a significant reduction in tumour growth without major 
toxicity (Segerstrom et al., 2006). A further study demonstrated that bevacizumab induces 
alterations in tumour vessels that, in turn, allows improved delivery and efficacy of 
chemotherapy (Dickson et al., 2007). Continuous treatment with low dose of vinblastine, a 
novel monoclonal anti-VEGFR-2 antibody (DC101) or both agents together have also been 
investigated(Klement et al., 2000). Both DC101 and low-dose vinblastine treatment 
individually resulted in significant, but ultimately transient, xenograft regression and 
decrease of tumour vascularity. Remarkably, the combination therapy resulted in a full and 
sustained regression of large established tumours, without any consequent increase in host 
toxicity or any signs of acquired drug resistance during the course of treatment which lasted 
more than 6 months. Activity of DC101 was also shown in a neuroblastoma cell line over-
expressing MYCN, in which tumour growth delay was increased by simultaneous 
irradiation (Gong et al., 2003). 
5.10 Inhibitors of the tyrosine kinase of VEGFRs 
SU5416, a specific inhibitor of VEGFR-1 and VEGFR-2, has been investigated as 
angiogenesis inhibitor strategy in neuroblastoma. Efficacy was increased when SU5416 was 
administered in combination with irradiation or chemotherapy (Backman et al., 2002). 
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5.11 Novel vascular targeting 
Tumour vascular targeting strategies that target and disrupt the existent vessel network of 
growing tumours have been actively perused (Sieman et al., 2004). Between them, vascular 
disrupting agents (VDAs), such as ligand-targeted and/or drug-conjugated liposomes have 
been recently introduced (Thorpe, 2004). Pastorino et al. have described a novel strategy of 
achieving an anti-neuroblastoma response using a peptide-targeted formulation of 
liposomal doxorubicin (Pastorino et al., 2003; Pastorino et al., 2006). This approach was 
active against both established primary tumours and early-phase metastases and induced a 
selective apoptosis of tumour endothelial cells and destruction of tumour vasculature. This 
novel strategy markedly enhanced the therapeutic use of doxorubicin and enabled 
metronomic administration. A dual mechanism of action has been proposed: indirect 
tumour cell killing via the destruction of tumour endothelium by NGR-targeted liposomes 
and direct tumour cell killing via localization of liposomal doxorubicin to the tumour 
interstitial space. This approach has been validated by evaluating tumour vasculature in 
several murine xenografts of doxorubicin-resistant human cancers, including lung, ovarian 
and neuroblastoma (Pastorino et al., 2008). The TVT-DOX used in this study was 
manufactured as large-scale Good Manufacturing Practice (GMP) preparation suited to 
human clinical trials. Opposing to the untargeted formulation of DOXIL®/CAELYX®, 
which has been approved for clinical use for the treatment of ovarian cancer and other solid 
tumours (Northfelt et al., 1997; Gordon et al., 2000), the GMP preparation of TVT-DOX has 
been demonstrated to effectively target the angiogenic tumour blood vessels and thus, 
indirectly, kill the tumour cells. Whereas tumour endothelial cell is well accepted as a valid 
target for cancer therapies, pericytes have been only recently recognized as a novel target for 
cancer treatment. The membrane associated protease APA is expressed in pericytes 
associated with tumour blood vessels and its expression has been correlated with tumour 
progression (Schlingemann et al., 1996; Marchio et al., 2004). Recently, Loi et al (2010) have 
developed a novel liposomal formulation targeting APA that displays anti-tumour effects 
and prolongs survival in human neuroblastoma-bearing mice with a significant increase in 
the level of apoptosis in tumours cells and a pronounced destruction of the tumour 
vasculature(Loi et al., 2010).  
6. Conclusion 
Angiogenesis in neuroblastoma has been thoroughly studied. As other solid tumours, the 
major role of angiogenesis resides in tumour development, maintenance and progression. 
These observations have led to the development of several different therapeutic strategies 
aimed to disrupt tumour vascularity. However, in designing novel therapeutic approaches a 
role of angiogenesis in promoting the mechanisms of maturation of neuroblastic cells has 
also to be considered. In fact, different angiogenetic pathways are involved in 
neuroblastoma, some of them sustaining tumour neo-angiogenesis and contributing to 
tumour aggressiveness and others contributing to the maturation of neuroblastic tumours. 
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